Ntjam NN, Thulliez M, Paintaud G, et al. - Electronic searches were performed in MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases from inception to July 7, 2020, to assess systemic adverse events (SAEs) associated with intravitreal anti-VEGF drugs compared with non–anti-VEGF treatments in patients with ocular diseases. In total, 74 randomized clinical trials have been analyzed: 32 trials (43%) included 14 190 patients with age-related macular degeneration (AMD), 24 (32%) included 5424 patients with diabetic retinopathy (diabetic macular edema or proliferative diabetic retinopathy), 17 trials (23%) included 3757 patients with retinal vein occlusion, and 1 trial (1%) included 122 patients with myopic choroidal neovascularization. In the trials examined herein, intravitreal anti-VEGF was not related to an increase in MACEs. Increased mortality in patients with diabetes and nonocular hemorrhages, particularly in those with AMD, could be a warning sign, but the evidence was inconclusive. However, continued monitoring of SAEs is still necessary.